UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of
earliest event reported) September 15, 2006
IT&E International Group, Inc.
|
| (Exact name of registrant as specified in its charter) |
Delaware
|
000-50095
|
20-4354185
|
| (State or other jurisdiction |
(Commission |
(IRS Employer |
| of incorporation) |
File Number) |
Identification No.) |
4 California Avenue, Framingham, Massachusetts
|
01701
|
| (Address of principal executive offices) |
(Zip Code) |
Registrant’s
telephone number, including area code 508-416-2600
|
| (Former name or former address, if changed since last report.) |
Check the appropriate box below if
the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions (see General Instruction A.2. below):
| [ ] |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| [ ] |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| [ ] |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
| [ ] |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) |
| Item 5.02 |
Departure
of Directors or Principal Officers; Election of Directors; Appointment of Principal
Officers |
(b) On
September 15, 2006, Kelly Alberts resigned from our board of directors (the
“Board”) and as our President. Mr. Albert’s resignations did not
relate to any disagreements with us on any matter related to our operations,
policies or practices. Mr. Alberts will continue on in a more limited role,
assisting us on a part-time basis. We have not yet identified a replacement for
Mr. Alberts on our Board.
(c) Effective
September 15, 2006, Dr. George Van Lear, 65, was appointed as Interim President of the
IT&E International division of our Company.
From
2000 to 2005, Dr. Van Lear served as Chair and President of aaiPharma’s research
division, where he led the internal Research and Development functions. Prior to
that, from 1999 to 2000, Dr. Van Lear served as President and Chief Operating Officer of
Senetek, PLC, a biotechnology firm. Dr. Van Lear started his career at Lederle
Laboratories from 1968-1984 where he was Group Leader in Drug Metabolism and Mass
Spectroscopy and then later as Head of the Analytical Services Department. From
1984 to 1999, Dr. Van Lear held a number of executive positions at Applied Analytical
Industries, Glaxo, Innapharma and DPT Laboratories. Dr. Van Lear earned his
undergraduate degree in Chemistry from Millikin University, a Ph.D. in Organic Chemistry
from the University of Utah as well as two postdoctoral fellowships at University of
Illinois and Purdue University.
Dr. Van
Lear’s employment will be at-will. He will receive a salary of $16,667 per
month. Dr. Van Lear will also be eligible to receive stock awards under our
2005 Equity Incentive Plan at the sole discretion of our Board.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
IT&E International Group, Inc. |
|
By: /s/ Dr. Philip T. Lavin |
|
Dr. Philip T. Lavin |
|
Chief Executive Officer |
Dated: September 19, 2006